





**Figure 2. Influenza Positive Tests and Percent Positive, Denton County Hospitals and Providers**




\* Percent positive tests only includes positive tests from providers reporting number of tests performed weekly

**Figure 3. Influenza Positive Tests Reported to CDC by U.S. Public Health Laboratories, National Summary, 2015-2016 Season**




**Figure 4. Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, 2015-2016 Season**




**Figure 5. U.S. Virologic Surveillance, Week 18 and Cumulative Data since October 4, 2015**

	Week 18	Data Cumulative since October 4, 2015 (Week 40)
No. of specimens tested	508	66,204
No. of positive specimens*	131	25,454
<i>Positive specimens by type/subtype</i>		
Influenza A	50 (38.2%)	18,251 (71.7%)
A(H1N1)pdm09	28 (56.0%)	14,556 (79.8%)
H3	19 (38.0%)	3,359 (18.4%)
Subtyping not performed	3 (6.0%)	336 (1.8%)
Influenza B	81 (61.8%)	7,203 (28.3%)
Yamagata lineage	37 (45.7%)	3,136 (43.5%)
Victoria lineage	17 (21.0%)	1,386 (19.2%)
Lineage not performed	27 (33.3%)	2,681 (37.2%)

**Figure 6. ESSENCE Syndromic Surveillance for Influenza-like Illness: Denton County  
September 1, 2015- May 7, 2016**



**Figure 7. ESSENCE Syndromic Surveillance for Influenza-like Illness: Denton County  
September 1, 2014 –May 7, 2016**



Data obtained from hospitals participating in the Electronic Surveillance System for the Early Notification of Community-based Epidemics (ESSENCE) from September 2015 through the present. Depicted are the numbers of persons presenting to Emergency Departments according to patient location (Denton region) with self-reported chief complaints of influenza-like illness.

**Figure 8. Antigenic Characterization of Influenza Isolates**

2009 Influenza A (H1N1)	900 of 901 (99.9%) – A/California/7/2009-like
Influenza A (H3N2)	516 of 516 (100%) – A/Switzerland/9715293/2013 similar
Influenza B (Yamagata Lineage)	390 of 390 (100%) – B/Phuket/3073/2013-like
Influenza B (Victoria Lineage)	307 of 314 (97.8%) – B/Brisbane/60/2008-like*

www.cdc.gov/flu/weekly

**2015-16 Influenza Vaccine Composition, Northern Hemisphere:**

- A/California/7/2009 (H1N1)-like virus
- A/Switzerland/9715293/2013 (H3N2)-similar virus
- B/Phuket/3073/2013-like virus
- B/Brisbane/60/2008-like virus\*


\* 2015-2016 Northern Hemisphere quadrivalent influenza vaccine influenza B component

**Figure 9. Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2015**


	Oseltamivir		Zanamivir		Peramivir	
	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)	Virus Samples tested (n)	Resistant Viruses, Number (%)
Influenza A (H1N1)pdm09	1,876	14 (0.7)	911	0 (0.0)	1,876	14 (0.7)
Influenza A (H3N2)	635	0 (0.0)	635	0 (0.0)	568	0 (0.0)
Influenza B	946	0 (0.0)	946	0 (0.0)	946	0 (0.0)

\*\*Antiviral treatment with oseltamivir, zanamivir, or peramivir is recommended as early as possible for patients with confirmed or suspected influenza who have severe, complicated, or progressive illness; who require hospitalization; or who are at high risk for serious influenza-related complications.

**Figure 10. Pneumonia and Influenza Mortality for 122 U.S. Cities:  
Week ending May 7, 2016**




**Figure 11. FluSurv-NET Laboratory-Confirmed Influenza Hospitalizations by Age Group,  
Preliminary data as of May 6, 2016**



The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and three additional states (MI, OH and UT).

FluView: Influenza Hospitalization Surveillance Network, Centers for Disease Control and Prevention. <http://www.cdc.gov/flu/weekly/>. Accessed on 5/13/16.


**Figure 12. FluSurv-NET Laboratory-Confirmed Influenza Hospitalizations: Selected Underlying Conditions 2015-16 Season, Preliminary data as of May 6, 2016**




The FluSurv-NET covers more than 70 counties in the 10 Emerging Infections Program (EIP) states (CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and three additional states (MI, OH and UT).

FluView: Influenza Hospitalization Surveillance Network, Centers for Disease Control and Prevention. <http://www.cdc.gov/flu/weekly/>. Accessed on 5/13/16.

**Figure 13. Weekly Influenza Activity Estimates Reported by State and Territorial Epidemiologists\* Week Ending May 7, 2016 – Week 18**



**Figure 14. Percentage of Respiratory Specimens that Tested Positive for Influenza: WHO, as of April 29, 2016**



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Data Source: Global Influenza Surveillance and Response System (GISRS), FluNet ([www.who.int/fluinet](http://www.who.int/fluinet)).



Please send inquiries to Briar Deen, MPH – Epidemiology Investigator  
Denton County Public Health at [Briar.Deen@dentoncounty.com](mailto:Briar.Deen@dentoncounty.com)